What is Iterative Health?
Iterative Health operates at the intersection of artificial intelligence and gastroenterology, providing sophisticated clinical tools designed to augment medical imaging and diagnostic accuracy. The company's core technology platform utilizes deep learning algorithms to assist physicians during endoscopic procedures, effectively reducing variability in detection and improving the consistency of clinical decision-making. By integrating seamlessly into existing hospital infrastructure, Iterative Health addresses critical gaps in gastrointestinal care, offering a scalable solution that enhances both the quality of patient diagnostics and the operational throughput of medical facilities. Its market position is defined by a commitment to evidence-based innovation, ensuring that clinicians are equipped with the most advanced digital assets to support high-stakes medical interventions.
How much funding has Iterative Health raised?
Iterative Health has raised a total of $257M across 3 funding rounds:
Series A
$30M
Series B
$150M
Series C
$77M
Series A (2021): $30M with participation from Johnson & Johnson Innovation, Seae Ventures, Breyer Capital, Eli Lilly, and Obvious Ventures
Series B (2022): $150M led by Breyer Capital, Clearlake Capital, Insight Partners, Johnson & Johnson, Obvious Ventures, and Eli Lilly
Series C (2026): $77M supported by The Obvious, EDBI, GV, Intrepid Growth Partners, and Insight Partners
Key Investors in Iterative Health
Insight Partners
Insight Partners is a global venture capital and private equity firm that invests in high-growth software and technology companies, providing capital and operational support to help businesses scale from early stage to IPO.
GV
GV is a venture capital firm that invests across multiple stages and sectors, focusing on enterprise solutions, life sciences, and frontier technology innovations globally.
EDBI
EDBI is a Singapore-based global investor focusing on high-growth technology sectors including biotechnology and fintech, aiming to catalyze growth and transform industries.
What's next for Iterative Health?
With the successful closure of this latest funding round, Iterative Health is well-positioned to expand its footprint in the enterprise healthcare market. The strategic roadmap focuses on deepening the integration of its AI systems within major hospital networks and broadening the scope of its diagnostic capabilities to encompass a wider range of gastrointestinal pathologies. Furthermore, the company is expected to prioritize the development of new data-driven insights that empower healthcare providers to make more informed, real-time decisions. As it scales, Iterative Health will likely continue to forge partnerships with leading medical institutions and technology stakeholders to solidify its role as an essential component of the modern digital health ecosystem.
See full Iterative Health company page
